Abstract

The antidiabetic and antioxidant effects of PROMAX-C were evaluated in male rats fed by hypercaloric sucrose diet supplemented with administration of dexamethasone. PROMAX-C at doses of 37.5, 75, 150 and 300mg/kg was administered by gavage in rats to assess its effect on the oral glucose tolerance test. The effects of this drug were also evaluated in a model of Type 2 Diabetes induced by a hypercaloric sucrose diet (MACAPOS 1 model) simultaneously with intraperitoneal administration of dexamethasone at a dose of 0.2mg/kg for 30 days. Metformin (20mg/kg) was administered as the reference drug. In the oral glucose tolerance test, administration of PROMAX-C showed a maximum reduction in blood glucose of 34.8% for the 300mg/kg dose 120 minutes after administration of PROMAX-C. This dose also significantly prevented increases in mean blood glucose (47.76%), triglycerides (41.38%), LDL cholesterol (61.88%), ALAT (21.79%) creatinine (60.17%) and HDL cholesterol (223.46%). This dose also significantly reduced MDA levels in the liver (64.6%) and kidneys (52.03%), Lastly, this dose significantly reduced MDA levels in the liver (64.6%) and kidneys (52.03%) but increased SOD, GSH and CAT levels by 5.8, 300 and 227 respectively in the liver of rats. The results of this study justify the use of PROMAX-C in the prevention and treatment of type 2 diabetes and its complications.

Keywords:Oxidative stress; PROMAX-C; MACAPOS; Dexamethasone

Abbreviations:ALAT: Alanine Aminotransferase; ASAT: Aspartate Aminotransferase; CAT: Catalase; GSH: Reduced Glutathione; HSD: Hypercaloric Sucrose Diet; IDF: International Diabetes Federation; MDA: Malondialdehyde; NO: Nitric Oxide; T1DM: Type 1 Diabetes Mellitus; T2DM: Type 2 Diabetes Mellitus; SOD: Superoxide Dismutase, IA: Atherogenic Index.